Elanco: Solid Momentum and Deleveraging Offset by Execution and Competitive Risks, Justifying a Hold Rating

Morgan Stanley analyst Erin Wright maintained a Hold rating on Elanco Animal Health yesterday and set a price target of $22.00.

Erin Wright has given his Hold rating due to a combination of factors reflecting both solid momentum and balanced risks. Elanco delivered stronger-than-expected quarterly results, with robust organic revenue growth supported by key companion and farm animal franchises, and management’s 2026 guidance broadly aligned with prior Investor Day targets on revenue, EBITDA, and EPS, while leverage is now projected to decline faster than initially planned.

At the same time, Wright notes that much of the upside depends on successful execution of Elanco’s late-stage innovation, including the IL-31 launch and other new products that must scale meaningfully by 2026, just as competitive pressures from potential new entrants intensify. With the FY26 outlook largely in line with existing expectations and shares already pricing in a good portion of the improved innovation contribution, the risk/reward appears balanced, warranting a Hold rather than a more aggressive rating.

In another report released today, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $28.00 price target.